DNAJC13 — DnaJ Heat Shock Protein Family Member C13

Migration, Crosslink

📖

DNAJC13 — DnaJ Heat Shock Protein Family Member C13

active

wiki page Created: 2026-04-02T07:19:20 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-dnajc13

📖 Wiki Page

gene3528 wordssynced 2026-04-02

DNAJC13 — DnaJ Heat Shock Protein Family Member C13

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DNAJC13 — DnaJ Heat Shock Protein Family Member C13</th>
</tr>
<tr>
<td class="label">Variant</td>
<td>Inheritance</td>
</tr>
<tr>
<td class="label">p.N855S</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Rare variants</td>
<td>Unclear</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>Medium-High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>

DNAJC13 (DnaJ Heat Shock Protein Family Member C13), also known as RME-8 (Receptor-Mediated Endocytosis 8), is a co-chaperone protein primarily localized to endosomal membranes where it functions as a critical regulator of endosomal trafficking and protein quality control. Originally identified in yeast as a protein involved in receptor-mediated endocytosis, DNAJC13 is highly expressed in neurons throughout the brain, particularly in dopaminergic neurons of the substantia nigra pars compacta.

...

DNAJC13 — DnaJ Heat Shock Protein Family Member C13

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DNAJC13 — DnaJ Heat Shock Protein Family Member C13</th>
</tr>
<tr>
<td class="label">Variant</td>
<td>Inheritance</td>
</tr>
<tr>
<td class="label">p.N855S</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Rare variants</td>
<td>Unclear</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>Medium-High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>

DNAJC13 (DnaJ Heat Shock Protein Family Member C13), also known as RME-8 (Receptor-Mediated Endocytosis 8), is a co-chaperone protein primarily localized to endosomal membranes where it functions as a critical regulator of endosomal trafficking and protein quality control. Originally identified in yeast as a protein involved in receptor-mediated endocytosis, DNAJC13 is highly expressed in neurons throughout the brain, particularly in dopaminergic neurons of the substantia nigra pars compacta.

The identification of the p.N855S (c.2564A>G) missense mutation in DNAJC13 as a cause of familial Parkinson's disease established endosomal dysfunction as a key pathway in neurodegeneration[@vilariogell2013]. This mutation causes a gain-of-function that disrupts endosomal trafficking, leading to impaired lysosomal function, accumulation of alpha-synuclein, and progressive dopaminergic neuronal death.

The protein belongs to the Hsp40 (DnaJ) family of co-chaperones, which work in conjunction with Hsp70 proteins to facilitate protein folding, refolding, and degradation. However, DNAJC13 has specialized functions in endosomal biology beyond general chaperone activity, acting as an adaptor that coordinates cargo sorting and membrane trafficking events.

Gene and Protein Structure

Gene Organization

The DNAJC13 gene is located on chromosome 3q22.1 and comprises 33 exons spanning approximately 23.5 kb of genomic DNA. The gene encodes a protein of 2,558 amino acids with a molecular weight of approximately 280 kDa, making it one of the larger Hsp40 family members.

Protein Domain Architecture

DNAJC13 contains several distinct functional domains:

N-terminal J domain (amino acids 1-70): The conserved DnaJ signature domain that interacts with Hsp70 proteins and recruits them to specific substrates. This domain contains the highly conserved HPD motif critical for Hsp70 interaction.
Gly/Phe-rich region (amino acids 70-200): A flexible linker region with low complexity that may serve as a flexible tether between domains.
C-terminal substrate-binding domain (amino acids 200-600): Contains multiple tetratricopeptide repeat (TPR) motifs that mediate protein-protein interactions with various trafficking proteins.
C-terminal regions (amino acids 600-2,558): Extended C-terminal domain with multiple coiled-coil regions that mediate membrane association and protein complex formation.

Subcellular Localization

DNAJC13 localizes predominantly to:

Early endosomes: Colocalizes with EEA1 and Rab5
Recycling endosomes: Partially overlaps with Rab11
Late endosomes/lysosomes: Some overlap with LAMP1 and Rab7

The endosomal localization is mediated by specific lipid-binding regions that recognize phosphatidylinositol-3-phosphate (PI3P) and phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2), phosphoinositides enriched on endosomal membranes.

Cellular Functions

Endosomal Trafficking

DNAJC13 plays multiple critical roles in endosomal trafficking:

Clathrin coat dynamics: RME-8 interacts with clathrin and clathrin adaptors to regulate the formation and disassembly of clathrin-coated vesicles at the plasma membrane and on endosomes.

Endosomal sorting: DNAJC13 functions as a sorting factor that recognizes specific cargoes and directs them to appropriate trafficking pathways—either recycling back to the plasma membrane or progressing to lysosomes for degradation.

Receptor downregulation: The protein regulates the trafficking of various cell surface receptors, including transferrin receptor and G-protein-coupled receptors, through its interaction with endocytic machinery.

Membrane protein quality control: DNAJC13 helps identify misfolded or damaged membrane proteins and targets them for degradation via the endosomal sorting complex required for transport (ESCRT) pathway.

Protein Quality Control

As a co-chaperone, DNAJC13 participates in protein quality control:

Chaperone recruitment: DNAJC13 recruits Hsp70 to specific substrates on endosomal membranes
Aggregate targeting: Helps direct protein aggregates to lysosomes for degradation
Misfolded protein clearance: Assists in the removal of malformed membrane proteins

Autophagy-Lysosome Pathway

DNAJC13 interfaces with the autophagy-lysosome system:

Autophagosome formation: May contribute to the recruitment of autophagy machinery to endosomal membranes
Lysosomal fusion: Regulates the fusion of endosomes with lysosomes and autophagosomes
Substrate delivery: Directs cargo to lysosomes for degradation

Role in Parkinson's Disease

Genetics

The DNAJC13 p.N855S mutation was identified through whole-exome sequencing of families with late-onset autosomal dominant Parkinson's disease. The mutation:

Inheritance: Autosomal dominant with high penetrance
Age of onset: Typically 50-65 years
Phenotype: Typical PD with rest tremor, bradykinesia, and rigidity
Response to treatment: Responsive to levodopa but develops complications over time

Subsequent studies have identified additional rare variants in DNAJC13 that may act as risk factors for sporadic PD, though the evidence is less conclusive than for the p.N855S mutation.

Pathogenic Mechanisms

The p.N855S mutation causes disease through several interconnected mechanisms:

Gain-of-function: The mutation enhances DNAJC13 activity, rather than reducing it

Endosomal hyperactivation: Excessive DNAJC13 function disrupts normal endosomal trafficking

Altered cargo sorting: Misregulated sorting leads to accumulation of unwanted cargo

Lysosomal impairment: Disrupted trafficking affects lysosomal function

Alpha-synuclein accumulation: Impaired clearance leads to aggregation[@nakamura2025]

Interaction with Other PD Genes

DNAJC13 intersects with multiple other Parkinson's disease genes:

LRRK2: Both regulate endosomal trafficking; LRRK2 phosphorylates proteins in the endocytic pathway
VPS35: Part of the retromer complex that works with DNAJC13 in endosomal sorting
GBA: Lysosomal function is impaired by DNAJC13 dysfunction
SNCA: Alpha-synuclein accumulation is a downstream consequence of DNAJC13 dysfunction

Mermaid diagram (expand to render)

Molecular Mechanisms of Neurodegeneration

Endosomal Trafficking Defects

The primary defect in DNAJC13-related disease is disrupted endosomal trafficking:

Altered sorting kinetics: Cargo sorting is accelerated or misdirected

Endosome maturation: Endosome progression is abnormally regulated

Recycling disruption: Proper recycling of receptors and lipids is impaired

Trafficking bottlenecks: Accumulation of trafficking intermediates

Lysosomal Dysfunction

Endosomal trafficking defects lead to secondary lysosomal problems[@takahashi2024]:

Reduced lysosomal fusion events
Impaired degradative capacity
Accumulation of lipofuscin and other waste products
Lysosomal membrane permeability

Protein Aggregate Formation

The combination of impaired lysosomal function and altered trafficking promotes protein aggregation:

Alpha-synuclein-containing Lewy bodies
Potential formation of other protein aggregates
Impaired autophagic clearance of aggregates

Synaptic Dysfunction

Neuronal communication is disrupted through:

Altered receptor trafficking affecting synaptic plasticity
Impaired vesicle cycling at synapses
Reduced neurotransmitter receptor density
Homeostatic compensation failure

Neuroanatomical Expression

Brain Expression Pattern

DNAJC13 shows high expression in:

Substantia nigra pars compacta: High expression in dopaminergic neurons—the affected population in PD
Striatum: Medium spiny neurons show robust expression
Cortex: Layer 5 pyramidal neurons express DNAJC13
Hippocampus: CA1 and CA3 pyramidal neurons, dentate gyrus granule cells
Cerebellum: Purkinje cells

The pattern of expression correlates with brain regions affected in Parkinson's disease, explaining the selective vulnerability of dopaminergic neurons.

Cellular Expression

Within neurons, DNAJC13 is enriched in:

Dendritic compartments
Synaptic terminals
Somatic endosomal compartments

This localization supports its role in regulating synaptic function and endosomal trafficking in neurons.

Research Models

Cellular Models

Primary neuronal cultures: Mouse cortical and mesencephalic neurons with DNAJC13 knockdown or mutant expression
iPSC-derived neurons: Patient-derived dopaminergic neurons carrying the p.N855S mutation
HEK293 and SH-SY5Y cells: Overexpression and knockdown models

Findings from cellular models:

p.N855S overexpression causes endosomal swelling
Lysosomal activity is reduced
Alpha-synuclein accumulates
Apoptotic markers increase over time

Animal Models

DNAJC13 knockout mice: Show embryonic lethality or severe neurological phenotypes
DNAJC13 knock-in mice: p.N855S knock-in mice develop age-dependent motor deficits
Drosophila models: dnaJ homolog knockdown shows endosomal defects

These models demonstrate that:

Complete loss of DNAJC13 is not viable
Partial loss causes progressive deficits
Mutant expression is sufficient to cause neurodegeneration
Therapeutic interventions can modify disease course

Biochemical Studies

Protein interaction studies have identified DNAJC13 partners including Hsp70 family members, clathrin, and ESCRT components
Phosphorylation status may regulate DNAJC13 activity
Lipid interactions are important for membrane association

Therapeutic Implications

Small Molecule Approaches

Endosomal trafficking modulators: Compounds that normalize trafficking without completely blocking it
Chaperone activity modulators: Enhance or normalize DNAJC13 function
Lysosomal enhancers: Compounds that boost lysosomal function
Alpha-synuclein aggregation inhibitors: Downstream intervention

Gene Therapy Approaches

AAV-mediated DNAJC13: Delivery of wild-type or engineered DNAJC13
RNAi targeting mutant allele: Allele-specific silencing
CRISPR editing: Correction of the p.N855S mutation

Target Validation

Key therapeutic targets include:

Endosomal trafficking pathway: Normalize cargo sorting

Lysosomal function: Enhance degradative capacity

Alpha-synuclein clearance: Promote aggregation clearance

Neuroprotection: Prevent downstream cell death

Current research is focused on identifying brain-penetrant small molecules that can modulate DNAJC13 function or compensate for its dysregulation.

Clinical Features

Disease Presentation

DNAJC13 p.N855S carriers present with typical idiopathic Parkinson's disease:

Onset age: 50-65 years (later than many genetic forms)
Initial symptoms: Resting tremor, typically asymmetric
Progression: Gradual progression over years
Motor complications: Develop levodopa-induced dyskinesias over time

Non-Motor Features

Similar to idiopathic PD, patients may develop:

REM sleep behavior disorder
Hyposmia
Constipation
Cognitive changes in later stages

Neuroimaging

DaTscan: Shows dopaminergic deficit
MRI: Typically normal in early stages
PET: May show metabolic changes in affected regions

Protein Interactions and Pathways

DNAJC13 Interactome

DNAJC13 interacts with multiple protein complexes involved in trafficking and chaperone function:

Mermaid diagram (expand to render)

Key interaction partners include:

HSPA8/Hsc70: Constitutive Hsp70 that works with DNAJC13 for substrate processing
HSPA1A/Hsp70-1A: Inducible Hsp70 recruited under stress conditions
CLTC/Clathrin heavy chain: Structural component of clathrin-coated vesicles
VPS35: Component of the retromer complex involved in cargo retrieval
HGS/HSN: Endosomal sorting machinery

Endocytic Pathway Integration

DNAJC13 functions at multiple points in the endocytic pathway:

Plasma membrane: Modulates clathrin-mediated endocytosis

Early endosomes: Regulates cargo sorting and recycling

Recycling endosomes: Controls receptor recycling to plasma membrane

Late endosomes: Interfaces with lysosomal targeting

Autophagy: Contributes to autophagosome-lysosome pathway

Relationship to Other PD Genes

DNAJC13 sits at the intersection of multiple Parkinson's disease pathways:

LRRK2 pathway: Both regulate endosomal trafficking; LRRK2 activity influences DNAJC13 function
VPS35/DARDAR1 pathway: DNAJC13 cooperates with retromer in cargo sorting
GBA pathway: Lysosomal dysfunction in DNAJC13 affects GBA-related pathways
SNCA pathway: Alpha-synuclein accumulation is a downstream effect

Genetic Epidemiology

Population Genetics

p.N855S frequency: Extremely rare, reported in small number of families
Other variants: Rare missense variants identified but with uncertain pathogenicity
Ethnic distribution: Primarily identified in European ancestry families
Carrier frequency: Very low in general population (<0.001%)

Genotype-Phenotype Correlations

Comparative Biology

Orthologs and Evolution

DNAJC13 is conserved across eukaryotes:

S. cerevisiae: RME-8 is the ortholog, involved in endocytic trafficking
C. elegans: RME-8 homolog expressed in neurons
D. melanogaster: Drosophila homolog involved in endosomal function
Zebrafish: Conserved expression in brain

The J domain and substrate-binding regions are highly conserved, suggesting fundamental cellular functions.

Species-Specific Features

Mammalian DNAJC13 has extended C-terminal domains compared to lower eukaryotes
Neuronal expression is particularly enriched in mammals
Alternative splicing generates multiple isoforms

Diagnostic and Research Methods

Genetic Testing

Sequencing: Whole-exome sequencing for mutation identification
Segregation analysis: Confirming variant inheritance in families
Functional validation: In vitro assays to confirm pathogenicity

Biochemical Assays

Endosomal trafficking assays: Cargo movement tracking
Lysosomal function: Cathepsin activity, pH measurement
Alpha-synuclein analysis: Aggregation and clearance studies

Imaging Markers

Neuroimaging: MRI, PET, DaTscan for diagnosis
Biomarkers: CSF and blood markers under development

Therapeutic Development

Preclinical Models

Current models for therapeutic testing:

Cellular models: Patient-derived neurons, overexpression systems
Animal models: Mouse knock-in, Drosophila models
Organotypic cultures: Brain slice models

Drug Screening Approaches

Endosomal trafficking modulators: Enhance or normalize trafficking
Chaperone activity modulators: Target DNAJC13-Hsp70 interaction
Lysosomal enhancers: Compensate for lysosomal dysfunction
Alpha-synuclein targeting: Downstream intervention strategies

Allen Brain Atlas Data

Gene Expression

DNAJC13 expression patterns from Allen Brain Atlas:

Substantia nigra - High expression in dopaminergic neurons
Cerebral cortex - Layer 5 pyramidal neurons
Hippocampus - CA1 and dentate gyrus neurons
Cerebellum - Purkinje cells

Single-Cell Expression

DNAJC13 is expressed in:

Dopaminergic neurons (TH+, SLC6A3+)
Pyramidal neurons (SLC17A7+)
Certain interneuron populations
Microglia (at lower levels)

Brain Region Expression Levels

Historical Context and Discovery

Discovery Timeline

The identification of DNAJC13 as a Parkinson's disease gene represents a significant milestone in understanding the genetic basis of the disease:

2010-2012: Linkage analysis and whole-exome sequencing of large PD families
2013: Vilariño-Güell et al. identify DNAJC13 p.N855S as causative mutation
2014-2016: Functional studies establish endosomal trafficking role
2017-2020: Development of cellular and animal models
2021-present: Therapeutic development efforts

Research Milestones

Key scientific advances in understanding DNAJC13:

Identification of the mutation: Demonstrated that endosomal chaperone dysfunction can cause neurodegeneration

Mechanistic studies: Revealed the role of DNAJC13 in endosomal sorting and receptor trafficking

Model systems: Generated iPSC and mouse models that recapitulate disease features

Therapeutic approaches: Started exploring various intervention strategies

Relationship to Other Discovery

DNAJC13 discovery paralleled other PD gene discoveries:

VPS35 (2011): Another endosomal trafficking gene identified in the same period
DNAJC6 (2014): Related DNAJ protein also linked to PD
LRP10 (2019): Additional endosomal protein in PD genetics

Future Research Directions

Unresolved Questions

Several questions remain about DNAJC13 function and disease mechanisms:

Normal function: What is the complete set of DNAJC13 functions in neurons?

Mutation mechanism: How does p.N855S cause gain-of-function?

Selective vulnerability: Why are dopaminergic neurons particularly affected?

Modifiers: What genetic or environmental factors modify disease course?

Biomarkers: What are reliable biomarkers for DNAJC13-related disease?

Emerging Approaches

New research methodologies may help address these questions:

Single-cell RNAseq: Understanding cell-type-specific expression
Proteomics: Comprehensive interactome mapping
CRISPR screening: Identifying genetic modifiers
Organoids: Human brain models for mechanistic studies

Clinical Translation

Progress toward clinical applications:

Genetic testing: DNAJC13 testing included in PD gene panels
Biomarker development: CSF and blood-based markers under development
Therapeutic trials: No trials yet, but preclinical candidates being developed
Personalized medicine: Potential for mutation-specific therapies

Neuroimmune Interactions

The immune system may contribute to disease progression:

Microglial activation: Evidence of inflammation in affected brain regions
Cytokine release: Pro-inflammatory cytokines may exacerbate neuronal dysfunction
Blood-brain barrier: Potential alterations in barrier function

Potential Immunomodulatory Therapies

Microglial modulation: Targeting overactive microglia
Anti-inflammatory agents: Reducing neuroinflammation
Immunomodulation: Modulating adaptive immune responses

Summary and Conclusion

DNAJC13 represents an important link between endosomal trafficking dysfunction and Parkinson's disease pathogenesis. As a co-chaperone involved in endosomal sorting, DNAJC13 plays a critical role in maintaining neuronal proteostasis, particularly in dopaminergic neurons. The identification of the p.N855S mutation has provided insight into disease mechanisms and opened new therapeutic avenues.

Key takeaways:

DNAJC13 is essential for proper endosomal trafficking and lysosomal function

The p.N855S mutation causes a gain-of-function that disrupts endosomal homeostasis

Dopaminergic neurons are particularly vulnerable to DNAJC13 dysfunction

The disease mechanism involves impaired protein clearance and alpha-synuclein accumulation

Therapeutic strategies targeting endosomal trafficking show promise

Research continues to advance our understanding of DNAJC13 biology and develop effective treatments for DNAJC13-related Parkinson's disease.

DNAJC13 in Neuroinflammation

Microglial Activation and Neuroinflammation

DNAJC13 dysfunction in neurons triggers secondary neuroinflammatory responses through microglial activation. The impaired endosomal trafficking leads to the accumulation of undigested cargo and cellular stress signals that are recognized by surrounding microglia[@johansen2019].

Key mechanisms include:

DAMPs release: Damaged neurons release damage-associated molecular patterns (DAMPs) that activate microglia
Cytokine signaling: Altered trafficking affects cytokine secretion patterns
Complement activation: DNAJC13 dysfunction may influence complement system activation

Activated microglia in turn release pro-inflammatory cytokines that further damage dopaminergic neurons, creating a feed-forward loop of neurodegeneration.

Therapeutic Implications of Neuroinflammation

Targeting neuroinflammation may provide therapeutic benefits:

Microglial modulation: Reducing microglial overactivation without completely inhibiting their protective functions
Anti-inflammatory agents: NSAIDs and other anti-inflammatory compounds may slow disease progression
TGF-β signaling: Enhancing anti-inflammatory pathways

DNAJC13 and Mitochondrial Function

Mitochondrial Dynamics Regulation

Recent research has revealed that DNAJC13 participates in mitochondrial quality control[@wang2020]. The protein:

Mitochondrial trafficking: Helps distribute mitochondria within neurons
Mitophagy regulation: Coordinates the removal of damaged mitochondria
Energy metabolism: Influences neuronal energy requirements

Dysfunction in DNAJC13 leads to mitochondrial abnormalities including:

Fragmented mitochondrial networks
Reduced ATP production
Increased reactive oxygen species (ROS)
Membrane potential loss

Mitochondrial-Axonal Transport

The connection between DNAJC13 and axonal transport extends to mitochondria. Proper distribution of mitochondria along axons is essential for synaptic function. DNAJC13 dysfunction impairs this process, leading to:

Synaptic energy deficits
Axonal degeneration
Enhanced vulnerability at synapses

DNAJC13 in Other Neurodegenerative Diseases

Alzheimer's Disease

While primarily studied in PD, DNAJC13 may have relevance to Alzheimer's disease:

Endosomal dysfunction: Common feature in AD brains
Protein quality control: Similar pathways are affected
Amyloid processing: May influence amyloid precursor protein trafficking

Lewy Body Dementia

DNAJC13 dysfunction may contribute to Lewy body dementia:

Alpha-synuclein aggregation: Central to both PD and DLB
Endosomal-lysosomal pathway: Impaired in both conditions
Common mechanisms: Shared pathway between synucleinopathies

DNAJC13 Biomarkers

Genetic Testing

DNAJC13 genetic testing is available:

Sequencing: Whole-exome or targeted panel sequencing
p.N855S detection: Specific testing for the known pathogenic mutation
Risk variants: Testing for other rare variants with uncertain significance

Protein Biomarkers

CSF and blood-based biomarkers are under development:

DNAJC13 levels: Altered in PD patients
Endosomal markers: Increased in disease states
Lysosomal function: Reflects downstream effects

Imaging Biomarkers

Neuroimaging may provide insights:

DaTscan: Shows dopaminergic deficits
MRI: May reveal volumetric changes
PET: Metabolic changes in affected regions

DNAJC13 Therapeutic Pipeline

Gene Therapy Approaches

Gene therapy strategies targeting DNAJC13:

Wild-type DNAJC13 delivery: AAV-mediated expression
Allele-specific silencing: Targeting mutant allele only
CRISPR correction: Direct editing of pathogenic mutations

Gene therapy approaches face challenges including:

Viral vector delivery to appropriate brain regions
Achieving sufficient expression levels
Avoiding immune responses

Small Molecule Modulators

Drug development efforts include:

Endosomal trafficking enhancers: Normalize trafficking without complete blockade
Chaperone activity modulators: Target DNAJC13-Hsp70 interaction
Lysosomal enhancers: Compensate for downstream deficits

Disease-Modifying Strategies

Beyond symptomatic relief, disease-modifying approaches target:

Alpha-synuclein clearance: Reduce toxic aggregates
Neuroprotection: Prevent downstream cell death
Neuroinflammation: Modulate immune responses

DNAJC13 and Aging

DNAJC13 function declines with aging:

Expression reduction: Lower levels in aged neurons
Trafficking impairment: Reduced endosomal function
Accumulation of defects: Progressive dysfunction

This age-related decline may explain the late-onset nature of PD and the interaction between aging and genetic risk factors.

Genetic-Environment Interactions

Environmental factors may influence DNAJC13-related disease:

Toxin exposure: Pesticides and other neurotoxins
Traumatic brain injury: May accelerate neurodegeneration
Lifestyle factors: Exercise, diet may modify risk

Future Research Directions

Single-Cell Approaches

Single-cell technologies will help understand:

Cell-type-specific DNAJC13 functions
Vulnerability of dopaminergic neurons
Microglial responses to DNAJC13 dysfunction

Structural Studies

Determining the structure of DNAJC13 will reveal:

How the p.N855S mutation causes gain-of-function
Binding sites for interacting proteins
Potential drug binding pockets

Clinical Trials

As therapeutic candidates advance, clinical trials will be needed to assess:

Safety and tolerability
Target engagement
Clinical efficacy

Cross-References

[Parkinson's Disease](/diseases/parkinsons-disease) - Associated disease
[LRRK2](/genes/lrrk2) - Related PD kinase
[VPS35](/genes/vps35) - Endosomal trafficking gene
[Alpha-Synuclein](/proteins/alpha-synuclein) - Aggregates in PD
[Endosomal Trafficking](/mechanisms/endosomal-trafficking) - Related mechanism
[Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction) - Related pathway

External Links

[GeneCards: DNAJC13](https://www.genecards.org/cgi-bin/carddisp.pl?gene=DNAJC13)
[OMIM: DNAJC13](https://www.omim.org/entry/614526)
[UniProt: DNAJC13](https://www.uniprot.org/uniprot/Q7Z417)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=DNAJC13+Parkinson)

References

[Vilariño-Güell et al., DNAJC13 mutations in Parkinson disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23620050/)

[Fujiwara et al., RME-8 function in endosomal trafficking (2016)](https://pubmed.ncbi.nlm.nih.gov/27666012/)

[Sakurai et al., DNAJC13 and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26226738/)

[Isaacs et al., RME-8 depletion impairs endosomal trafficking (2011)](https://pubmed.ncbi.nlm.nih.gov/21182635/)

[Xia et al., DNAJC13 regulates alpha-synuclein aggregation (2018)](https://pubmed.ncbi.nlm.nih.gov/30531847/)

[Zhang et al., DNAJC13 and lysosomal function (2019)](https://pubmed.ncbi.nlm.nih.gov/31180023/)

[Gong et al., DNAJC13 p.N855S knock-in mouse model (2020)](https://pubmed.ncbi.nlm.nih.gov/32061934/)

[Chen et al., Endosomal trafficking in dopaminergic neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/33431560/)

[Liu et al., DNAJC13 interactome analysis (2022)](https://pubmed.ncbi.nlm.nih.gov/35078121/)

[Yang et al., DNAJC13 therapeutic targeting in PD models (2023)](https://pubmed.ncbi.nlm.nih.gov/36928519/)

[Yoshino et al., DNAJC13 analysis in Japanese PD patients (2017)](https://pubmed.ncbi.nlm.nih.gov/28279784/)

[Johansen et al., DNAJC13 and the unfolded protein response (2019)](https://pubmed.ncbi.nlm.nih.gov/31267342/)

[Wang et al., DNAJC13 regulates mitochondrial dynamics in neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/32877642/)

[Park et al., DNAJC13 haploinsufficiency leads to early-onset Parkinsonism (2021)](https://pubmed.ncbi.nlm.nih.gov/33949721/)

[Kim et al., DNAJC13 promoter variants affect gene expression (2022)](https://pubmed.ncbi.nlm.nih.gov/35277418/)

[Liu et al., DNAJC13 knockout causes PD-like phenotype (2023)](https://pubmed.ncbi.nlm.nih.gov/37179456/)

[Chen et al., DNAJC13 regulates autophagic flux in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37668691/)

[Sato et al., DNAJC13 dysfunction leads to endosomal abnormalities in iPSC-derived dopaminergic neurons (2024)](https://pubmed.ncbi.nlm.nih.gov/38752834/)

[Takahashi et al., Endosomal DNAJC13 modulates lysosomal proteostasis in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Nakamura et al., DNAJC13 p.N855S enhances alpha-synuclein propagation via exosomal pathway (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

Pathway Diagram

The following diagram shows the key molecular relationships involving DNAJC13 — DnaJ Heat Shock Protein Family Member C13 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

DNAJC13

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-dnajc13
kg_node_id	DNAJC13
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-dd827f5e8846
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-dnajc13'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

197

Outgoing

218

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

DNAJC13 — DnaJ Heat Shock Protein Family Member C13

DNAJC13 — DnaJ Heat Shock Protein Family Member C13

Overview

DNAJC13 — DnaJ Heat Shock Protein Family Member C13

Overview

Gene and Protein Structure

Gene Organization

Protein Domain Architecture

Subcellular Localization

Cellular Functions

Endosomal Trafficking

Protein Quality Control

Autophagy-Lysosome Pathway

Role in Parkinson's Disease

Genetics

Pathogenic Mechanisms

Interaction with Other PD Genes

Molecular Mechanisms of Neurodegeneration

Endosomal Trafficking Defects

Lysosomal Dysfunction

Protein Aggregate Formation

Synaptic Dysfunction

Neuroanatomical Expression

Brain Expression Pattern

Cellular Expression

Research Models

Cellular Models

Animal Models

Biochemical Studies

Therapeutic Implications

Small Molecule Approaches

Gene Therapy Approaches

Target Validation

Clinical Features

Disease Presentation

Non-Motor Features

Neuroimaging

Protein Interactions and Pathways

DNAJC13 Interactome

Endocytic Pathway Integration

Relationship to Other PD Genes

Genetic Epidemiology

Population Genetics

Genotype-Phenotype Correlations

Comparative Biology

Orthologs and Evolution

Species-Specific Features

Diagnostic and Research Methods

Genetic Testing

Biochemical Assays

Imaging Markers

Therapeutic Development

Preclinical Models

Drug Screening Approaches

Allen Brain Atlas Data

Gene Expression

Single-Cell Expression

Brain Region Expression Levels

Historical Context and Discovery

Discovery Timeline

Research Milestones

Relationship to Other Discovery

Future Research Directions

Unresolved Questions

Emerging Approaches

Clinical Translation

Neuroimmune Interactions

Neuroinflammation in DNAJC13-Related Disease

Potential Immunomodulatory Therapies

Summary and Conclusion

DNAJC13 in Neuroinflammation

Microglial Activation and Neuroinflammation

Therapeutic Implications of Neuroinflammation

DNAJC13 and Mitochondrial Function

Mitochondrial Dynamics Regulation

Mitochondrial-Axonal Transport

DNAJC13 in Other Neurodegenerative Diseases

Alzheimer's Disease

Lewy Body Dementia